Future of Biomanufacturing: AI-Driven Cell Line Development and Bioprocess Design

Biotech, Fundamental Research, Life Science, Pharma, Pharma Manufacturing & Supply Chain,
  • Wednesday, May 28, 2025 | 12pm EDT / 9am PDT / 5pm BST / 6pm CEST
  • 60 min

Traditional approaches to biologics production—relying on one-size-fits-all expression vectors and empirical process optimization—have led to inefficiencies in expression, scalability and manufacturability.

While incremental improvements in cell line engineering and bioprocess modeling have driven progress, the rapid evolution of artificial intelligence (AI) and digital tools is poised to revolutionize biopharmaceutical process development and manufacturing.

In this webinar, the expert speaker will present a vision for the future of biologics production and discuss the progress towards holistic optimal design of cell lines, genetic systems and bioprocesses.

Register for this webinar today to understand how biomanufacturing is evolving with the use of AI in cell line development and bioprocess design.

Keywords:
Register

Speaker

Thibault Laurent, Asimov

Thibault Laurent, Director, Strategic Alliance, Asimov

Thibault Laurent is a seasoned expert in cell line development and genome engineering with over 12 years of experience in the biopharmaceutical industry. His work has focused on stable cell line development for biologics production and the application of genome editing technologies such as CRISPR/Cas9 and rAAV to create advanced cell models for disease research, target identification and validation.

Thibault has held various roles at Synthego and Horizon Discovery, and now serves as Director, Strategic Alliance at Asimov, a Boston-based company leveraging synthetic biology to advance biologics and viral vector production systems.

Message Presenter

Message Presenter

Have questions or would like more information? Use the form below to send a message.

Who Should Attend?

This webinar will appeal to:

  • Cell line development scientists
  • CMC scientists
  • Scientists with a biological lead looking to move into stable cell line production

What You Will Learn

Attendees will learn about:

  • The CHO Edge system, which is an integrated platform for genetic design as well as cell line and process development
  • How high-titer clones (7–11 g/L) can be delivered in under four months across monoclonal and bispecific antibodies
  • Integrating multi-omics and bioreactor-scale models to further optimize growth, productivity and quality

Xtalks Partner

Asimov Logo

Asimov

Asimov’s mission is to advance humanity’s ability to design living systems, enabling biotechnologies with outsized societal benefit. The company is developing a synthetic biology platform – from cells to software – to design and manufacture next-generation therapeutics, including biologics, cell/gene therapies, and RNA through a combination of products, services, and collaborations. Founded by bioengineers from MIT and Boston University and headquartered in Boston, the company has raised over $200 million from top institutional investors including Andreessen Horowitz, CPP Investments, Horizons Ventures, and Fidelity Management & Research Company. For more information, visit www.asimov.com.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account